[Ip-health] Chronic hepatitis C treatment outcomes in low- and middle-income countries

Joanna Keenan-Siciliano joanna.l.keenan at gmail.com
Thu Sep 13 09:12:12 PDT 2012


In case you missed it, please see the link below to the first article that
systematically assesses Hepatitis C treatment results outside developed
countries, published in the July issue of WHO Bulletin: "Chronic hepatitis
C treatment outcomes in low- and middle-income countries: a systematic
review and meta-analysis."  The study shows that outcomes in low- and
middle- income countries are just as successful as in developed countries,
lending further support that treatment should be prioritized. Up to now,
there has been reluctance to treat Hep C in resource-limited settings,
partly out of concerns that treatment is too complex to manage in these
settings.

Cost is a huge issue and needs to be addressed: the average cost of
treatment is around $18,000 dollars/patient, although locally-produced
medicines have recently become available at much lower cost. This study
comes at a time of great scientific progress related to the treatment of
Hepatitis C, and new drugs coming out soon would make treatment much easier
in developing countries (making it fully oral treatment). Their entry to
developing countries should be prioritized but high prices will be a huge
barrier to patients actually receiving these new medicines.

http://www.who.int/bulletin/volumes/90/7/11-097147.pdf


Joanna Keenan
Press Officer
Médecins Sans Frontières - Access Campaign
E: joanna.keenan[at]geneva.msf.org
T: twitter.com/joanna_keenan

msfaccess.org
twitter.com/MSF_access
facebook.com/MSFaccess



More information about the Ip-health mailing list